Clifford Chance

Clifford Chance advises INKEF Capital, Vesalius Biocapital, Index Ventures and Gilde Healthcare Partners in respect of their investment in Profibrix B.V

Amsterdam, 4 May 2011 – International law firm Clifford Chance advised Vesalius Biocapital, INKEF Capital, Index Ventures and Gilde Healthcare Partners  in the successful closing of a series B follow-on investment of Profibrix B.V., a leader in the development of innovative products for the hemostasis and regenerative medicine markets. In addition to the private funding, the Company was awarded a government credit, bringing the total new funds available to the company to EUR 15 million (USD 22 million).

Herke van Hulst, counsel who led the transaction, commented, "The transaction represents a highly successful example of a  venture capital transaction in the healthcare sector. We are very pleased to have advised the investors in this transaction."

The Clifford Chance team consisted of Amsterdam counsel Herke van Hulst (lead),  Jodie Lazell (corporate) and Hein van den Hout (employment).